Jump to main content or search this site.


Search this site, or jump to top of the page.

Perlmutter Cancer Center Highlights

Perlmutter Cancer Center Highlights 2019–2020

Breakthrough: FDA Approves First Treatment in 22 Years for a Common Type of Bladder Cancer

Trial provides new options for bacillus Calmette-Guérin–unresponsive non-muscle invasive type.

Read Story

Explore the Issue

Browse All Issues

Search this site, or jump to top of the page.

Search this site, or jump to top of the page.

Current site Current page